Stay updated on Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial page
- Check4 days agoChange DetectedThe page now includes a dedicated Locations section listing study sites in Illinois, Indiana, Iowa, Minnesota, and Wisconsin. The separate Illinois Locations entry and related footer label have been removed as part of this update.SummaryDifference0.6%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check33 days agoChange DetectedThe page's revision label was updated from v3.2.0 to v3.3.2, a minor administrative change that does not affect study content or details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check40 days agoChange DetectedThe government funding notice at the bottom of the page was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check54 days agoChange DetectedNo significant changes detected in core study information (enrollment, eligibility, sites, dosing, or outcomes). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check83 days agoChange DetectedMajor addition of a government funding notice and upgrade to v3.2.0, replacing v3.1.0; references to operating status and status inquiries are now present.SummaryDifference3%

- Check90 days agoChange DetectedUpdated contact details and a new software revision (v3.1.0) replacing the old v3.0.2; added multiple phone numbers and emails.SummaryDifference0.1%

Stay in the know with updates to Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial page.